Literature DB >> 21141286

The impact of hydroxyurea on career and employment of patients with sickle cell anemia.

Samir K Ballas1, Robert L Bauserman, William F McCarthy, Myron A Waclawiw.   

Abstract

The purpose of this study was to determine the association between hydroxyurea treatment and changes in employment status, if any, among patients with sickle cell anemia enrolled in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). To that end, we compared the employment status among treatment responders, treatment nonresponders, and placebo groups of patients enrolled in MSH during the clinical trial and follow-up periods. Treatment with hydroxyurea did not significantly (p > .05) affect employment status, but there was a trend for more consistent employment in the hydroxyurea group. Given the fact that patients enrolled in MSH had moderate to severe disease with irreversible complications such as avascular necrosis, if would be attractive to hypothesize that future treatment of young patients with hydroxyurea could prevent or mitigate the incidence of complications of sickle cell anemia and, hence, improve the employment status of treated patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21141286

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  10 in total

1.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

2.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

3.  Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Authors:  Javier Bolaños-Meade; Kenneth R Cooke; Christopher J Gamper; Syed Abbas Ali; Richard F Ambinder; Ivan M Borrello; Ephraim J Fuchs; Douglas E Gladstone; Christian B Gocke; Carol Ann Huff; Leo Luznik; Lode J Swinnen; Heather J Symons; Stephanie A Terezakis; Nina Wagner-Johnston; Richard J Jones; Robert A Brodsky
Journal:  Lancet Haematol       Date:  2019-03-14       Impact factor: 18.959

Review 4.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Angela E Rankine-Mullings; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2022-09-01

5.  Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.

Authors:  Hyeun Ah Kang; Jamie C Barner; Kristin M Richards; Menaka Bhor; Jincy Paulose; Abdullah Kutlar
Journal:  J Health Econ Outcomes Res       Date:  2020-06-26

Review 6.  Blood and marrow transplantation for sickle cell disease: is less more?

Authors:  Javier Bolaños-Meade; Robert A Brodsky
Journal:  Blood Rev       Date:  2014-08-27       Impact factor: 8.250

Review 7.  Sickle cell disease: a natural model of acute and chronic pain.

Authors:  Amanda M Brandow; Katherine J Zappia; Cheryl L Stucky
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

Review 8.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Sarah J Nevitt; Ashley P Jones; Jo Howard
Journal:  Cochrane Database Syst Rev       Date:  2017-04-20

9.  Impact of sickle cell disease on work activity.

Authors:  Rosana Paula Pires; Mário Cézar Oliveira; Lucio Borges Araújo; João Carlos Oliveira; Tânia Machado Alcântara
Journal:  Rev Bras Med Trab       Date:  2022-06-30

10.  Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.

Authors:  Jennifer N Longoria; Norma L Pugh; Victor Gordeuk; Lewis L Hsu; Marsha Treadwell; Allison A King; Robert Gibson; Mariam Kayle; Nancy Crego; Jeffrey Glassberg; Cathy L Melvin; Jane S Hankins; Jerlym Porter
Journal:  Am J Hematol       Date:  2021-08-24       Impact factor: 10.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.